fashion -WSS

fashion

author：knowledge 2025-09-27 23:11:49 - browse：83

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Rep. Raul Ruiz on the physician shortage and more

hotspot

WSS

Bird flu in dairy cattle: New measures to control spread to humans

First Opinion on colorectal cancer screening: letter and response

Scientists uncover potential path to treating deadly childhood tumor

J&J to emphasize cancer drugs, stop much of its vaccine research

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

With clinical trial data readouts, here's how to spot spin

knowledge

fashion

focus

Malaria cases in Florida and Texas: Here’s what you need to know

What don’t we know about an Alzheimer’s drug side effect?

Duchenne breakthrough therapy leaves behind pioneering families

Drug companies' payments and gifts affect physicians' prescribing

Guidelines to prevent youth baseball injuries need more muscle

How to pay for weight loss drugs and save Medicare

Activists slam private health insurers over coverage restrictions

Mayo Clinic plans $5B tech

Alkermes shareholders re

What to do when lifesaving products contribute to climate change

focus

Four alarming medical procedures we’re glad history forgot

U.K. Biobank has 500,000 peoples' genome sequences available

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Drug companies' payments and gifts affect physicians' prescribing

Will the market for weight loss drugs really reach $100 billion?

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

hotspot

hotspot

knowledge

Wikipedia